At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Patrick Forde, MD, makes the case for chemotherapy plus immuno-oncology as the best treatment for patients with lung cancer who have a PD-L1 expression of ≥50%.

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

Is there a difference in L858R mutation rates in EGFR-mutated lung cancer when stratified by stage?